Christopher Michael Camarra
Director · Hoth Therapeutics, Inc.
Individual
- 2026
- May 28, 2026
- 1
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Christopher Michael Camarra's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Mark A. Goldsmith - $56.99M in RVMD purchases and sales in the last 12 months
- Peter A. Thompson - $55.67M in SION purchases and sales in the last 12 months
- ORBIMED ADVISORS LLC - $55.67M in SION purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $55.46M in COAG purchases and sales in the last 12 months
- John E. Kao - $54.16M in ALHC purchases and sales in the last 12 months
- Mahkam Zanganeh - $51.95M in SMMT purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Christopher Michael Camarra?
Christopher Michael Camarra is a corporate insider, tracked as Director of Hoth Therapeutics, Inc. (RKTO). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Christopher Michael Camarra last file a Form 4?
The only primary Form 4 on record is dated 28 May 2026.